Basel, 04 May 2017
Save the date: Roche Analyst Event at ISTH 2017
Monday, 10 July 2017, 6:30pm CEST
We kindly invite investors and analysts to participate in an analyst briefing during the International Society on Thrombosis and Hemostasis Congress (ISTH) in Berlin 8 - 13 July 2017.
During the briefing, Roche will discuss new data for emicizumab (ACE910) in hemophilia A:
HAVEN1 - phase 3 study of emicizumab (ACE910) prophylaxis in persons with hemophilia A with inhibitors
HAVEN2 - phase 3 study of emicizumab (ACE910) in pediatric persons with hemophilia A with inhibitors
Venue
Hotel Berlin, Berlin
Lützowplatz 17
10785 Berlin
Germany
map
Date/Time
Monday, 10 July 2017 @ 6:30pm CEST
The briefing will be followed by a buffet reception.
An invitation with the detailed programme and registration form will follow shortly.
Best regards,
Karl Mahler
Head of Investor Relations
Sabine Borngräber
Investor Relations Officer
Roche Holding AG published this content on 04 May 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 04 May 2017 08:09:20 UTC.
Original documenthttp://www.roche.com/investors/updates/inv-update-2017-05-04.htm
Public permalinkhttp://www.publicnow.com/view/68F887406B5E206F4350D84E96DDB9A80C11950D